NYSE:GSK News 2 December 2025

GSK Stock News Today (Dec. 17, 2025): FDA Approves Twice‑Yearly Asthma Drug Exdensur as Analysts Reassess GSK plc’s 2026 Outlook

Updated: 17 December 2025 GSK plc stock (LSE: GSK; NYSE: GSK) is in focus on Dec. 17 after a major U.S. regulatory win: the FDA approved Exdensur (depemokimab‑ulaa) for severe asthma—giving GSK a new, ultra‑long‑acting biologic that’s dosed just twice

17 December 2025

GSK plc Stock News Today (16.12.2025): Exdensur UK Approval Puts GSK Shares in Focus as FDA Decision Looms

December 16, 2025 — GSK plc stock (LSE: GSK; NYSE: GSK) is firmly on investors’ radar today after a cluster of late-year regulatory catalysts across respiratory, vaccines, and infectious diseases — the kind of headline flow that can reshape sentiment

16 December 2025

FDA Updates · Investment News · NYSE:GSK · Pharmaceuticals · Stock Market · UK Regulatory Approvals

GSK plc Stock News & Forecasts (Dec. 15, 2025): FDA Catalyst for Depemokimab, EU Backs Nucala and Arexvy, Analysts Map the Path Ahead

GSK plc Stock News & Forecasts (Dec. 15, 2025): FDA Catalyst for Depemokimab, EU Backs Nucala and Arexvy, Analysts Map the Path Ahead GSK plc stock (LSE: GSK, NYSE: GSK) is ending 2025 with a rare “cluster” of market-moving catalysts

15 December 2025

Biotech Forecasts · FDA Updates · Investment Analysis · NYSE:GSK · Pharma News · Stock Market

GSK Stock News Today (Dec. 12, 2025): Arexvy EU Expansion, Blujepa FDA Approval, Analyst Forecasts and What’s Next

Published: 12 December 2025 GSK plc stock is back in focus on Friday as investors digest a fast-moving cluster of regulatory headlines across vaccines, infectious diseases and oncology—alongside ongoing buybacks and fresh consensus forecasts that map out how GSK’s revenue

12 December 2025

Analyst Insights · FDA Approvals · Investment Trends · NYSE:GSK · Pharmaceutical Industry · Stock Market News

GSK’s Emma Walmsley Hails US as ‘Best Place to Invest’ as UK Pharma Faces Tariffs, Rebate Cuts and a Fight for Jobs

On 11 December 2025, outgoing GSK chief executive Dame Emma Walmsley sent a stark message to Westminster and the City: for big drug makers, the United States is now the premier destination for investment – and Britain is at risk

11 December 2025

Business News · Healthcare Policy · Investment · NYSE:AZN · NYSE:GSK · Pharma Industry · UK Economy

GSK Stock on 10 December 2025: FDA Orphan-Drug Win, New Cancer Deal and What It Means for Investors

GSK plc (LSE: GSK; NYSE: GSK) is ending 2025 in full “pipeline flex” mode. On 10 December 2025 the company announced fresh US regulatory momentum for an experimental lung cancer drug and a new oncology collaboration, while the share price

10 December 2025

Cancer Research · FDA Approvals · Investment Analysis · NYSE:GSK · Pharmaceuticals · Stock Market

GSK Stock Near 52-Week Highs: Upgraded 2025 Guidance, Buybacks and Zantac Relief Fuel Re‑Rating

As of 9 December 2025, GSK plc (LSE: GSK; NYSE: GSK) stock is trading close to its 52‑week highs on both sides of the Atlantic, after a year in which the UK pharma group has upgraded guidance, accelerated buybacks and

9 December 2025

Company Analysis · Financial News · Investment Strategies · NYSE:GSK · Pharmaceuticals · Stock Market

GSK Stock Today, December 8, 2025: Price, Buyback, CEO Change and 2026 Forecast

Updated 8 December 2025 GSK share price snapshot GSK plc (LON: GSK; NYSE: GSK) heads into the second week of December trading near its 52‑week highs after a year of strong execution in specialty medicines and a powerful buyback programme.

8 December 2025

CEO Updates · Financial Forecasts · GSK News · Investment Analysis · NYSE:GSK · Stock Market

GSK plc Stock in December 2025: Buybacks, New CEO and Strong Q3 Results Drive a 40% Rally

GSK share price today, latest news, dividend, buyback activity and stock forecast as of 5 December 2025. GSK Share Price: Trading Near Multi‑Year Highs After a Strong 2025 GSK plc (LON:GSK; NYSE:GSK) is heading into year‑end 2025 on the front

5 December 2025

Corporate News · Investment Strategies · Market Analysis · NYSE:GSK · Pharmaceuticals · Stocks

GSK Stock Near 52‑Week High as FDA Decisions and CEO Transition Loom (LON:GSK, NYSE:GSK)

GSK plc’s share price is pressing against 52‑week highs as 2025 draws to a close, with investors weighing a cluster of near‑term FDA decisions, a major CEO change on 1 January 2026, and a still‑busy share buyback programme. As of

4 December 2025

FDA · GSK · Market News · NYSE:GSK · Pharmaceuticals · Stocks

GSK Stock Outlook December 2025: Q3 Beat, Buybacks and Big FDA Decisions Shape 2026 Forecasts

As of December 3, 2025, GSK plc (LSE:GSK, NYSE:GSK) is trading near multi‑year highs after a year of earnings beats, a revived oncology franchise, heavy share buybacks and an unusually busy FDA calendar for December. At the same time, analysts

3 December 2025

FDA Updates · Investment Strategies · Market Forecasts · NYSE:GSK · Pharma News · Stock Analysis

GSK plc Stock Today: Q3 Beat, Blenrep Comeback and a New CEO – Full Investor Update for 2 December 2025

GSK plc (LSE: GSK, NYSE: GSK) heads into the final month of 2025 near multi‑year highs, powered by a strong run of earnings beats, a revived oncology franchise and a looming change at the top of the company. As of

2 December 2025

CEO News · Earnings Reports · Investor Updates · NYSE:GSK · Pharmaceuticals · Stock Market

NYSE:GSK News 2 December 2025 - 17 December 2025